V.F.Snegirev Archives of Obstetrics and GynecologyV.F.Snegirev Archives of Obstetrics and GynecologyАрхив акушерства и гинекологии им. В.Ф. Снегирева2313-87262687-1386Eco-Vector3543210.18821/2313-8726-2018-5-3-116-127Original study articlesОригинальные исследованияOriginal study articlesReview ArticleACUTE CYSTITE: CURRENT ISSUES OF DIAGNOSTICS AND ANTIMICROBIAL THERAPYОСТРЫЙ ЦИСТИТ: АКТУАЛЬНЫЕ ВОПРОСЫ ДИАГНОСТИКИ И АНТИМИКРОБНОЙ ТЕРАПИИKaptilnyyVitaly A.КаптильныйВиталий Александрович

MD, PhD, leading researcher of Research Department of Women’s Health of Research Center, Assistant of the Department of Obstetrics and Gynecology No 1 of the I.M. Sechenov First Moscow State Medical University, Moscow, 119991, Russian Federation

канд. мед. наук, доцент каф. акушерства и гинекологии № 1 лечебного факультета ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России

1mgmu@mail.ruMikhailovaV. IМихайловаВ. ИI.M. Sechenov First Moscow State Medical UniversityФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский университет)1509201853VOL 5, NO3 (2018)ТОМ 5, №3 (2018)11612721072020Copyright ©; 2018, Eco-VectorCopyright ©; 2018, ООО "Эко-Вектор"2018Eco-VectorООО "Эко-Вектор"https://archivog.com/2313-8726/article/view/35432

The review considers modern data on the diagnosis and treatment of acute cystitis. Questions of epidemiology and etiology of acute cystitis are covered. Regimens of basic and alternative treatment for acute cystitis are presented in terms of the perspective of evidence-based medicine.

В обзоре рассматриваются современные данные о диагностике и лечении острого цистита. Освещены вопросы эпидемиологии и этиологии острого цистита. Приводятся основные и альтернативные схемы лечения острого цистита с позиции доказательной медицины.

urinary tract infectioncystitisинфекция мочевыводящих путейциститFoxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect. Dis. Clin. North. Am. 2014; 28:1Schappert S.M., Rechtsteiner E.A. Ambulatory medical care utilization estimates for 2007. Vital. Health Stat. Series 13. 2011; (169): 1Материалы международного симпозиума «Инфекции мочевыводящих путей у амбулаторных больных». М.; 1999.Никонов А.П., Асцатурова О.Р. Инфекции в акушерстве и гинекологии. Практическое руководство по диагностике и антимикробной химиотерапии. Инфекции и антимикробная терапия. 2004; 6 (3): 176-8.Каптильный В.А. Инфекция мочевыводящих путей во время беременности. Архив акушерства и гинекологии им. В.Ф. Снегирева. 2015; 2 (4): 10-9.Hooton T.M., Scholes D., Hughes J.P. et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. N. Engl. J. Med. 1996; 335: 468.Scholes D., Hooton T.M., Roberts P.L. et al. Risk factors associated with acute pyelonephritis in healthy women. Ann. Intern. Med. 2005; 142: 20.Czaja C.A., Scholes D., Hooton T.M., Stamm W.E. Population-based epidemiologic analysis of acute pyelonephritis. Clin. Infect. Dis. 2007; 45: 273.Echols R.M., Tosiello R.L., Haverstock D.C., Tice A.D. Demographic, clinical, and treatment parameters influencing the outcome of acute cystitis. Clin. Infect. Dis. 1999; 29:113.Hooton T.M. Clinical practice. Uncomplicated urinary tract infection. N. Engl. J. Med. 2012; 366: 1028.Gupta K., Trautner B. In the clinic. Urinary tract infection. Ann. Intern. Med. 2012; 156:ITC3.Hooton T.M., Roberts P.L., Cox M.E., Stapleton A.E. Voided midstream urine culture and acute cystitis in premenopausal women. N. Engl. J. Med. 2013; 369: 1883.Khawcharoenporn T., Vasoo S., Singh K. Urinary tract infections due to multidrug-resistant Enterobacteriaceae: prevalence and risk factors in a Chicago Emergency Department. Emerg. Med. Int. 2013; 2013: 258517. doi: 10.1155/2013/258517Killgore K.M., March K.L., Guglielmo B.J. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann. Pharmacother. 2004; 38:1148.Walker E., Lyman A., Gupta K., et al. Clinical management of an increasing threat: outpatient urinary tract infections due to multidrug-resistant uropathogens. Clin. Infect. Dis. 2016; 63: 960.Smithson A., Chico C., Ramos J., et al. Prevalence and risk factors for quinolone resistance among Escherichia coli strains isolated from males with community febrile urinary tract infection. Eur. J. Clin. Microbiol. Infect. Dis. 2012; 31: 423.Linsenmeyer K., Strymish J., Gupta K. Two simple rules for improving the accuracy of empiric treatment of multidrug-resistant urinary tract infections. Antimicrob. Agents Chemother. 2015; 59: 7593.Kahlmeter G. Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study. Int. J. Antimicrob. Agents. 2003; 22 Suppl 2: 49.Kahlmeter G., ECO.SENS. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J. Antimicrob. Chemother. 2003; 51: 69.Naber K.G., Schito G., Botto H., et al. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur. Urol. 2008; 54:1164.Zhanel G.G., Hisanaga T.L., Laing N.M., et al. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int. J. Antimicrob. Agents. 2006; 27: 468.Sanchez G.V., Master R.N., Karlowsky J.A., Bordon J.M. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob. Agents Chemother. 2012; 56: 2181.Swami S.K., Liesinger J.T., Shah N., et al. Incidence of antibiotic-resistant Escherichia coli bacteriuria according to age and location of onset: a population-based study from Olmsted County, Minnesota. Mayo Clin. Proc. 2012; 87: 753.Gupta K., Hooton T.M., Miller L. Uncomplicated UTI IDSA Guideline Committee. Managing uncomplicated urinary tract infection-making sense out of resistance data. Clin. Infect. Dis. 2011; 53: 1041.Gupta K. Emerging antibiotic resistance in urinary tract pathogens. Infect. Dis. Clin. North Am. 2003; 17: 243.Miller L.G., Tang A.W. Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance. Mayo Clin. Proc. 2004; 79:1048.Paterson D.L. “Collateral damage” from cephalosporin or quinolone antibiotic therapy. Clin. Infect. Dis. 2004; 38 Suppl. 4: S341.Schito G.C., Naber K.G., Botto H., et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int. J. Antimicrob. Agents. 2009; 34: 407.Lautenbach E. Editorial commentary: flying under the radar: the stealth pandemic of Escherichia coli sequence type 131. Clin. Infect. Dis. 2013; 57: 1266.Bent S., Nallamothu B.K., Simel D.L., et al. Does this woman have an acute uncomplicated urinary tract infection? J. Am. Med. Assoc. 2002; 287:2701.Mody L., Juthani-Mehta M. Urinary tract infections in older women: a clinical review. J. Am. Med. Assoc. 2014; 311:844.Juthani-Mehta M., Quagliarello V., Perrelli E., et al. Clinical features to identify urinary tract infection in nursing home residents: a cohort study. J. Am. Geriatr. Soc. 2009; 57: 963.Sundvall P.D., Ulleryd P., Gunnarsson R.K. Urine culture doubtful in determining etiology of diffuse symptoms among elderly individuals: a cross-sectional study of 32 nursing homes. BMC Fam. Pract. 2011; 12: 36.Sundvall P.D., Elm M., Ulleryd P., et al. Interleukin-6 concentrations in the urine and dipstick analyses were related to bacteriuria but not symptoms in the elderly: a cross sectional study of 421 nursing home residents. BMC Geriatr. 2014; 14: 88.Nace D.A., Drinka P.J., Crnich C.J. Clinical uncertainties in the approach to long-term care residents with possible urinary tract infection. J. Am. Med. Dir. Assoc. 2014; 15:133.Coyne K.S., Sexton C.C., Vats V. et al. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011; 77: 1081.Sand P.K., Goldberg R.P., Dmochowski R.R. et al. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am. J. Obstet. Gynecol. 2006; 195: 1730.Gupta K., Hooton T.M., Roberts P.L., Stamm W.E. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch. Intern. Med. 2007; 167: 2207.Hooton T.M., Winter C., Tiu F., Stamm W.E. Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women. J. Am. Med. Assoc. 1995; 273: 41.Singh N., Gandhi S., McArthur E., et al. Kidney function and the use of nitrofurantoin to treat urinary tract infections in older women. Can. Med. Assoc. J. 2015; 187: 648.Arredondo-García J.L., Figueroa-Damián R., Rosas A., et al. Comparison of short-term treatment regimen of ciprofloxacin versus long-term treatment regimens of trimethoprim/sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract infections: a randomized, multicentre, open-label, prospective study. J. Antimicrob. Chemother. 2004; 54: 840.Gupta K. Emerging antibiotic resistance in urinary tract pathogens. Infect. Dis. Clin. North Am. 2003; 17: 243.Raz R., Chazan B., Kennes Y., et al. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin. Infect. Dis. 2002; 34: 1165.Potts L., Cross S., MacLennan W.J., Watt B. A double-blind comparative study of norfloxacin versus placebo in hospitalised elderly patients with asymptomatic bacteriuria. Arch. Gerontol. Geriatr. 1996; 23: 153.Huttner A., Kowalczyk A., Turjeman A., et al. Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: A randomized clinical trial. J. Amer. Med. Assoc. 2018. doi:10.1001/jama.2018.3627.Ferry S.A., Holm S.E., Stenlund H., et al. Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: the LUTIW project. Scand. J. Prim. Health Care. 2007; 25: 49.Graninger W. Pivmecillinam-therapy of choice for lower urinary tract infection. Int. J. Antimicrob. Agents. 2003; 22 Suppl 2: 73.Hooton T.M., Roberts P.L., Stapleton A.E. Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. J. Amer. Med. Assoc. 2012; 307: 583.Rodríguez-Baño J., Alcalá J.C., Cisneros J.M., et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch. Intern. Med. 2008; 168: 1897.Henry D., Ellison W., Sullivan J., et al. Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group. Antimicrob. Agents Chemother. 1998; 42: 2262.Richard G.A., Mathew C.P., Kirstein J.M., et al. Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens. Urology. 2002; 59: 334.Fourcroy J.L., Berner B., Chiang Y.K., et al. Efficacy and safety of a novel once-daily extended-release ciprofloxacin tablet formulation for treatment of uncomplicated urinary tract infection in women. Antimicrob. Agents Chemother. 2005; 49: 4137.Little P., Moore M.V., Turner S., et al. Effectiveness of five different approaches in management of urinary tract infection: randomised controlled trial. Brit. Med. J. 2010; 340: c199.Qiao L.D., Chen S., Yang Y., et al. Characteristics of urinary tract infection pathogens and their in vitro susceptibility to antimicrobial agents in China: data from a multicenter study. Brit. Med. J. Open. 2013; 3: e004152.Jansåker F., Frimodt-Møller N., Sjögren I., Dahl Knudsen J. Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections. J. Antimicrob. Chemother. 2014; 69: 769.Kronenberg A., Bütikofer L., Odutayo A., et al. Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial. Brit. Med. J. 2017; 359: j4784.Klimberg I., Shockey G., Ellison H., et al. Time to symptom relief for uncomplicated urinary tract infection treated with extended-release ciprofloxacin: a prospective, open-label, uncontrolled primary care study. Curr. Med. Res. Opin. 2005; 21: 1241.